51463-73-1

Upstream product

• 1126779-19-8 tert-butyl 4-(4-cyanophenyl)-3,5-dimethyl-1H-pyrazole-1-carboxylate 
• 1073354-70-7 tert-butyl 3,5-dimethyl-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-pyrazole-1-carboxylate 
• 623-00-7 4-bromobenzenecarbonitrile 

Downstream Products

• 1126776-90-6 4-[3,5-dimethyl-1-(pyrazin-2-ylmethyl)-1H-pyrazol-4-yl]benzonitrile 
• 1126776-84-8 4-[3,5-dimethyl-1-(1,3-thiazol-5-ylmethyl)-1H-pyrazol-4-yl]benzonitrile 
• 1126776-77-9 4-{1-[(2-fluoropyridin-4-yl)methyl]-3,5-dimethyl-1H-pyrazol-4-yl}benzonitrile 
• 1126776-62-2 4-{3,5-dimethyl-1-[(1-methyl-1H-1,2,3-benzotriazol-5-yl)methyl]-1H-pyrazol-4-yl}benzonitrile 
• 1126770-93-1 4-[1-(4-fluorobenzyl)-3,5-dimethyl-1H-pyrazol-4-yl]benzonitrile 

Relevant academic research and scientific papers

SUBSTITUTED PYRAZOLE DERIVATIVES

The present invention provides a novel pyrazole derivative and an androgen receptor antagonist containing the derivative. The present invention provides a compound represented by the formula (I′) wherein R1 is a hydrogen atom, a group via a carbon atom, a group via a nitrogen atom, a group via an oxygen atom, or a group via a sulfur atom; R2 is a phenyl group having cyano (the phenyl group may further have substituent(s) other than cyano); R3 is a hydrogen atom, a group via a carbon atom, a group via a nitrogen atom, a group via an oxygen atom, or a group via a sulfur atom; R4 is a cyclic group optionally having substituent(s); and X is methylene optionally having substituent(s), or CO, or a salt thereof.